Biodexa Pharmaceuticals Plc
corporate_fare Company Profile
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 49 items for BDRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-14, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for BDRX spans 6-K, 424B3, F-1, F-1/A.
Recent high-impact activity:
- Biodexa Hits 100-Patient Enrollment in Phase 3 Serenta Trial; Futility Analysis Pulled Forward to Early 2027
- Biodexa Announces 1-for-8 Reverse ADS Split Effective October 26
- Biodexa Sets 1-for-8 ADS Reverse Split Effective October 26
- Biodexa Sets 1-for-8 ADS Reverse Split Effective October 26
- Biodexa Sets 1-for-8 Reverse ADS Split for October 26
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 919,936 shares in BDRX as of the October 15, 2026 settlement, a 4905.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 2, 2026, 26.0% of BDRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for BDRX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-14.
Multi-Part Offering Finalized · Discounted Pricing
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
BDRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.